Weiss Ratings Reaffirms “Sell (D-)” Rating for BioNTech (NASDAQ:BNTX)

BioNTech (NASDAQ:BNTX)‘s stock had its “sell (d-)” rating reiterated by analysts at Weiss Ratings in a report issued on Tuesday,Weiss Ratings reports.

Several other research analysts have also issued reports on the stock. Bank of America increased their price target on shares of BioNTech from $126.00 to $134.00 and gave the stock a “buy” rating in a research note on Tuesday, August 5th. Morgan Stanley decreased their price target on shares of BioNTech from $133.00 to $131.00 and set an “overweight” rating for the company in a research note on Friday, October 10th. JPMorgan Chase & Co. increased their price target on shares of BioNTech from $116.00 to $121.00 and gave the stock a “neutral” rating in a research note on Monday, September 22nd. Wells Fargo & Company set a $150.00 price target on shares of BioNTech and gave the stock an “overweight” rating in a research note on Tuesday, August 5th. Finally, HC Wainwright reiterated a “buy” rating and issued a $136.00 price target on shares of BioNTech in a research note on Monday, September 8th. Ten analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $134.32.

BioNTech Trading Up 1.7%

NASDAQ:BNTX opened at $104.34 on Tuesday. The company has a 50-day moving average price of $104.01 and a 200-day moving average price of $103.68. BioNTech has a 12 month low of $81.20 and a 12 month high of $129.27. The company has a current ratio of 8.61, a quick ratio of 8.48 and a debt-to-equity ratio of 0.01. The stock has a market cap of $25.08 billion, a price-to-earnings ratio of -65.21 and a beta of 1.45.

BioNTech (NASDAQ:BNTX) last posted its earnings results on Monday, August 4th. The company reported ($1.60) EPS for the quarter, missing the consensus estimate of ($1.41) by ($0.19). BioNTech had a negative return on equity of 1.84% and a negative net margin of 12.20%.The company had revenue of $306.46 million during the quarter, compared to analysts’ expectations of $161.26 million. During the same period in the prior year, the business posted ($3.36) earnings per share. The company’s revenue for the quarter was up 102.6% on a year-over-year basis. BioNTech has set its FY 2025 guidance at EPS. Equities analysts predict that BioNTech will post -3.88 EPS for the current year.

Institutional Trading of BioNTech

A number of large investors have recently made changes to their positions in BNTX. Banque Cantonale Vaudoise bought a new stake in shares of BioNTech in the first quarter worth approximately $36,000. LRI Investments LLC grew its stake in shares of BioNTech by 234.6% in the second quarter. LRI Investments LLC now owns 445 shares of the company’s stock worth $47,000 after acquiring an additional 312 shares during the period. Tower Research Capital LLC TRC grew its stake in shares of BioNTech by 118.2% in the second quarter. Tower Research Capital LLC TRC now owns 563 shares of the company’s stock worth $60,000 after acquiring an additional 305 shares during the period. Hantz Financial Services Inc. grew its stake in shares of BioNTech by 472.0% in the second quarter. Hantz Financial Services Inc. now owns 572 shares of the company’s stock worth $61,000 after acquiring an additional 472 shares during the period. Finally, GAMMA Investing LLC grew its stake in shares of BioNTech by 40.8% in the third quarter. GAMMA Investing LLC now owns 784 shares of the company’s stock worth $77,000 after acquiring an additional 227 shares during the period. 15.52% of the stock is currently owned by institutional investors.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.